Lung Cancer Europe shared a post by Antonious Z. Hazim, Hematology Medical Oncology Fellow at Mayo Clinic, Rochester Minnesota, on X, adding:
“A lot of recent discussion about ICI pneumonitis in lung cancer. This new study is an important step in understanding who’s most at risk, how to manage it, and when it might be safe to restart treatment. We often hear from people excluded from trials or left with limited options after serious ICI toxicity. More research like this helps protect access, reduce harm, and support better treatment decisions. Thanks Antonious Z. Hazim, Mayo Clinic.”
Quoting Antonious Z. Hazim‘s post
“ICI pneumonitis remains a significant challenge for our patients. Honored to have led this study. Thank you to my mentors.”
Title: Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis
Journal: Cancer Immunology, Immunotherapy
Authors: Antonious Hazim, Irene Riestra Guiance, Jacob Shreve, Gordon Ruan, Damian McGlothlin, Allison LeMahieu, Robert Haemmerle, Keith Mcconn, Richard C. Godby, Lisa Kottschade, Anna Schwecke, Casey Fazer-Posorske, Tobias Peikert, Eric Edell, Konstantinos Leventakos, Ashley Egan
Read Full Article.
More posts about Lung Cancer on OncoDaily.